MedTrace Logo

Efficacy and Safety of the Anti- COVID-19 Vaccin in Clinical Hematology Patients

NCT04852796 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2023-08-30

No results posted yet for this study

Summary

Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in December 2019 in Wuhan, China. Infection with this new coronavirus called SARS-CoV-2 can lead to fatal pneumonia associated with high rates of hospitalization in intensive care units (ICU).

Hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs. 8%). The severity of Covid-19 may be related to their treatment, in particular anti-CD20 used in B lymphoid hemopathies. In fact, anti-CD20 antibodies induce rapid and prolonged depletion of B cells, but they are necessary for development. humoral immune responses.

But currently, no immunogenicity data are known for patients with hemopathy or in those on anti-lymphocyte immunochemotherapy.

Conditions

  • Covid19
  • Hematologic Malignancy
  • Vaccine Response Impaired

Interventions

OTHER

Patients with hemopathy

optimal humoral response at 1 month after COVID-19 vaccination

Sponsors & Collaborators

  • Centre Hospitalier de Cornouaille

    lead OTHER

Principal Investigators

  • LENAIG LE CLECH, PhD · Centre Hospitalier de Quimper Cornouaille

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-04-01
Completion
2023-04-01

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04852796 on ClinicalTrials.gov